Clinical validation of fiberoptic immunobiosensor for point-of-care analysis of plasma nerve growth factor

Liang Tang, Yong Seog Oh, Hongmei Li, Juan Song, Peng-Sheng Chen, Shien-Fong Lin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Upregulation of plasma nerve growth factor (NGF) is indicative of cardiac nerve sprouting that is underlying the mechanisms for cardiac arrhythmias. A conventional assay method (e.g., enzyme-linked immunosorbent assay [ELISA]) is usually time consuming and technically complicated for NGF analysis for potential arrhythmia prognosis. Objective: This study is to develop a rapid and and reliable assay method for point-of-care (POC) testing of plasma NGF. Methods: We recently developed a fiberoptic immunobiosensor for point-of-care testing of human plasma NGF. Physiological concentrations of NGF (1 to 200 ng/ml) could be quantified in both buffer and human blood plasma samples (100 μl) within 5 min. The intra-assay coefficient of variation was 5%, and the interassay coefficient of variation was 8%. The clinical utility of the NGF biosensor was evaluated using clinical blood samples from atrial fibrillation patients (n = 21). Peripheral venous blood was sampled before and immediately after radiofrequency ablation and again at postoperative day 1. Results: The NGF level did not change significantly between before (15.73 ± 16.67 ng/ml) and immediately after radiofrequency ablation (13.58 ± 11.45 ng/ml, P = NS); however, there was a significant elevation to 28.41 ± 19.52 ng/ml in postoperative day 1 (P

Original languageEnglish (US)
Pages (from-to)1208-1213
Number of pages6
JournalHeart Rhythm
Volume4
Issue number9
DOIs
StatePublished - Sep 2007
Externally publishedYes

Fingerprint

Point-of-Care Systems
Nerve Growth Factor
Cardiac Arrhythmias
Biosensing Techniques
Atrial Fibrillation
Buffers
Up-Regulation
Enzyme-Linked Immunosorbent Assay

Keywords

  • Cardiac arrhythmia
  • Cardiac biomarkers
  • Cardiovascular disease diagnosis
  • Fiberoptic biosensor
  • Nerve growth factor
  • Point-of-care testing

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical validation of fiberoptic immunobiosensor for point-of-care analysis of plasma nerve growth factor. / Tang, Liang; Oh, Yong Seog; Li, Hongmei; Song, Juan; Chen, Peng-Sheng; Lin, Shien-Fong.

In: Heart Rhythm, Vol. 4, No. 9, 09.2007, p. 1208-1213.

Research output: Contribution to journalArticle

@article{c030c6f0a4bc4338a5947ae1a91d80f6,
title = "Clinical validation of fiberoptic immunobiosensor for point-of-care analysis of plasma nerve growth factor",
abstract = "Background: Upregulation of plasma nerve growth factor (NGF) is indicative of cardiac nerve sprouting that is underlying the mechanisms for cardiac arrhythmias. A conventional assay method (e.g., enzyme-linked immunosorbent assay [ELISA]) is usually time consuming and technically complicated for NGF analysis for potential arrhythmia prognosis. Objective: This study is to develop a rapid and and reliable assay method for point-of-care (POC) testing of plasma NGF. Methods: We recently developed a fiberoptic immunobiosensor for point-of-care testing of human plasma NGF. Physiological concentrations of NGF (1 to 200 ng/ml) could be quantified in both buffer and human blood plasma samples (100 μl) within 5 min. The intra-assay coefficient of variation was 5{\%}, and the interassay coefficient of variation was 8{\%}. The clinical utility of the NGF biosensor was evaluated using clinical blood samples from atrial fibrillation patients (n = 21). Peripheral venous blood was sampled before and immediately after radiofrequency ablation and again at postoperative day 1. Results: The NGF level did not change significantly between before (15.73 ± 16.67 ng/ml) and immediately after radiofrequency ablation (13.58 ± 11.45 ng/ml, P = NS); however, there was a significant elevation to 28.41 ± 19.52 ng/ml in postoperative day 1 (P",
keywords = "Cardiac arrhythmia, Cardiac biomarkers, Cardiovascular disease diagnosis, Fiberoptic biosensor, Nerve growth factor, Point-of-care testing",
author = "Liang Tang and Oh, {Yong Seog} and Hongmei Li and Juan Song and Peng-Sheng Chen and Shien-Fong Lin",
year = "2007",
month = "9",
doi = "10.1016/j.hrthm.2007.05.031",
language = "English (US)",
volume = "4",
pages = "1208--1213",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Clinical validation of fiberoptic immunobiosensor for point-of-care analysis of plasma nerve growth factor

AU - Tang, Liang

AU - Oh, Yong Seog

AU - Li, Hongmei

AU - Song, Juan

AU - Chen, Peng-Sheng

AU - Lin, Shien-Fong

PY - 2007/9

Y1 - 2007/9

N2 - Background: Upregulation of plasma nerve growth factor (NGF) is indicative of cardiac nerve sprouting that is underlying the mechanisms for cardiac arrhythmias. A conventional assay method (e.g., enzyme-linked immunosorbent assay [ELISA]) is usually time consuming and technically complicated for NGF analysis for potential arrhythmia prognosis. Objective: This study is to develop a rapid and and reliable assay method for point-of-care (POC) testing of plasma NGF. Methods: We recently developed a fiberoptic immunobiosensor for point-of-care testing of human plasma NGF. Physiological concentrations of NGF (1 to 200 ng/ml) could be quantified in both buffer and human blood plasma samples (100 μl) within 5 min. The intra-assay coefficient of variation was 5%, and the interassay coefficient of variation was 8%. The clinical utility of the NGF biosensor was evaluated using clinical blood samples from atrial fibrillation patients (n = 21). Peripheral venous blood was sampled before and immediately after radiofrequency ablation and again at postoperative day 1. Results: The NGF level did not change significantly between before (15.73 ± 16.67 ng/ml) and immediately after radiofrequency ablation (13.58 ± 11.45 ng/ml, P = NS); however, there was a significant elevation to 28.41 ± 19.52 ng/ml in postoperative day 1 (P

AB - Background: Upregulation of plasma nerve growth factor (NGF) is indicative of cardiac nerve sprouting that is underlying the mechanisms for cardiac arrhythmias. A conventional assay method (e.g., enzyme-linked immunosorbent assay [ELISA]) is usually time consuming and technically complicated for NGF analysis for potential arrhythmia prognosis. Objective: This study is to develop a rapid and and reliable assay method for point-of-care (POC) testing of plasma NGF. Methods: We recently developed a fiberoptic immunobiosensor for point-of-care testing of human plasma NGF. Physiological concentrations of NGF (1 to 200 ng/ml) could be quantified in both buffer and human blood plasma samples (100 μl) within 5 min. The intra-assay coefficient of variation was 5%, and the interassay coefficient of variation was 8%. The clinical utility of the NGF biosensor was evaluated using clinical blood samples from atrial fibrillation patients (n = 21). Peripheral venous blood was sampled before and immediately after radiofrequency ablation and again at postoperative day 1. Results: The NGF level did not change significantly between before (15.73 ± 16.67 ng/ml) and immediately after radiofrequency ablation (13.58 ± 11.45 ng/ml, P = NS); however, there was a significant elevation to 28.41 ± 19.52 ng/ml in postoperative day 1 (P

KW - Cardiac arrhythmia

KW - Cardiac biomarkers

KW - Cardiovascular disease diagnosis

KW - Fiberoptic biosensor

KW - Nerve growth factor

KW - Point-of-care testing

UR - http://www.scopus.com/inward/record.url?scp=34548256791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548256791&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2007.05.031

DO - 10.1016/j.hrthm.2007.05.031

M3 - Article

C2 - 17765623

AN - SCOPUS:34548256791

VL - 4

SP - 1208

EP - 1213

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 9

ER -